Skip to main content
. 2015 Jul 29;10(7):e0131565. doi: 10.1371/journal.pone.0131565

Table 2. Number of observations of serum IgG below the target.

Period of study Subjects < 12 y Subjects ≥ 12 y
Observations Patients (N = 15) Observations Patients (N = 34)
n IgG <4 g/L n IgG <4 g/L n IgG <6 g/L n IgG <6 g/L
Pre-Subgam 21 1 11 1 75 5 34 3
Stage 1, months 0 to 6 a 122 3 15 1 463 16 34 5
Stage 2, months
>6 to 12 b 18 0 13 0 61 5 30 3
>12 to 18 16 0 11 0 61 5 27 4
>18 to 24 16 0 10 0 64 8 27 4
>24 to 30 14 0 8 0 58 8 28 4
>30 to 36 16 0 10 0 46 2 26 2
>36 to 42 5 0 4 0 32 7 21 4
>42 to 48 2 0 2 0 22 3 16 3
>48 to 54 0 0 0 0 8 1 7 1
Total in Stage 2 87 0 13 0 352 39 30 6

a Stage 1 lasted approximately 6 months, depending upon the number of infusions received by the patient and contains post-Subgam data only

b This interval lasted approximately 6 months, from the first infusion in Stage 2 until 12 months after the first infusion of Subgam